Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study V Sanchorawala, S Sarosiek, A Schulman, M Mistark, ME Migre, R Cruz, ... Blood, The Journal of the American Society of Hematology 135 (18), 1541-1547, 2020 | 138 | 2020 |